Oppenheimer: 3 Stocks That Could Surge Over 100% From Current Levels
So far, September has been a wild ride of ups and downs. Following the recent bout of volatility, stocks have ticked higher again. But as uncertainty regarding another rescue program and the presidential election continues to linger, where does the market go from here? Weighing in for Oppenheimer, Chief Investment Strategist John Stoltzfus argues that any market dips appear “relatively contained and orderly,” and present longer-term investors the chance to find “babies that got thrown out with the bathwater.” He noted, “For nervous investors the recent downdraft has presented opportunity to take some profits without FOMO (fear of missing out).”As for the tech heavyweights that powered the market’s five-month charge forward, the strategist believes “current expectations that technology stocks will remain under pressure for some time seem exaggerated.” Stoltzfus adds that the “core of technology stocks did not appear terribly rich in price considering that developments in technology and innovation have yet to show signs of plateauing in the current cycle.”Taking Stoltzfus’ outlook into consideration, our focus turned to stocks that Oppenheimer analysts are bullish on. The firm’s pros see triple-digit upside potential in store for three tickers in particular. Running the names through TipRanks’ database, we wanted to find out what makes each so compelling.MediWound Ltd. (MDWD)Developing cutting-edge products, MediWound wants to address unmet needs in the fields of severe burn and chronic wound management. With an important government contract secured, Oppenheimer has high hopes for this name.Back in January, MDWD announced that the U.S. Biomedical Advanced Research and Development Authority (BARDA) had entered into a contract to procure $16.5 million of NexoBrid, its drug designed to remove eschar in adults with deep partial and full-thickness thermal burns (a process called debridement), for an emergency stockpile. According to management, the first delivery is set for Q3 2020.On top of this, the company filed the NexoBrid Biologics License Application (BLA) with the FDA for eschar removal in adults with deep partial-thickness and full-thickness thermal burns in June. MDWD’s U.S. commercial partner, Vericel, is preparing for an immediate launch upon approval.Representing Oppenheimer, 5-star analyst Kevin DeGeeter points out that “Given the filing involved participation from three parties—MDWD, U.S. commercial partner Vericel and funding partners at BARDA—and was completed against the backdrop of public sector work-from-home mandates, we view meeting stated timelines as a material milestone and derisking event for MDWD shares… we believe NexoBrid is on track for 1H21 launch.”Should the therapy ultimately be approved, MDWD is entitled to a $7.5 million milestone payment from Vericel. “We believe the combination of existing cash and the $7.5 million milestone payment from VCEL upon NexoBrid approval should fund operations at least into 2H23,” DeGeeter added.DeGeeter also points out that MDWD plans to open 25-30 sites in U.S. and Israel to support the Phase 2 study of EscharEx, its product for chronic wounds. Although COVID-19 resulted in a delay, the analyst thinks “the current timeline of 1H21 is achievable.”To this end, DeGeeter rates MDWD an Outperform along with a $7 price target. Should his thesis play out, a potential twelve-month gain of 117% could be in the cards. (To watch DeGeeter’s track record, click here)All in all, other analysts echo DeGeeter’s sentiment. 4 Buys and no Holds or Sells add up to a Strong Buy consensus rating. With an average price target of $6.63, the upside potential comes in at 106%. (See MDWD stock analysis on TipRanks)UroGen Pharma (URGN)Primarily focused on uro-oncology, UroGen Pharma develops advanced non-surgical treatments to improve the lives of patients. As the launch of one of its products is progressing well, Oppenheimer thinks that now is the time to get on board.Writing for the firm, analyst Leland Gershell points to UGN-101 as a key component of his bullish thesis. UGN-101, which has now been formally launched in the U.S. under the commercial name Jelmyto, was designed as a treatment for low-grade upper tract urothelial carcinoma (LG UTUC). The analyst highlights that Jelmyto’s launch is already off to a solid start, as eight patients had received 20 doses of the drug in June.“Jelmyto sales were $371,000 in its first month of launch, but more important was management’s commentary that over 100 urology practice sites are treatment-ready for the product, and that patient demand has not been visibly impacted by COVID-19,” Gershell explained.Adding to the good news, permanent C- and J-codes, which are expected in October and January 2021, respectively, could bolster sales, in Gershell’s opinion. The label could also be updated to reflect completed OLYMPUS data.It should be noted that patient and physician engagement could remain diminished through YE20, and restrictions around elective surgeries could persist, according to Gershell. That said, he argues that “LG UTUC’s lack of surgical urgency could imply treatment deferral for several months, whereas Jelmyto’s ability to be administered in an outpatient setting could expedite treatment, favoring adoption.”If that wasn’t enough, UGN-102, its mitomycin gel that targets low-grade intermediate risk non-muscle invasive bladder cancer (LG IR-NMIBC), is set to enter pivotal testing before the end of 2020. Looking at previously released data, the therapy achieved a 65% complete response (CR) rate at three months following onset of treatment. “To offset any potential COVID-19 impact on enrollment, URGN has increased the number of clinical trial sites outside of the U.S., in those countries where virus-related clinical delays have not cropped up,”Gershell added.Summing it all up, Gershell commented, “We believe shares trade at a discount to the value of Jelmyto and UGN-102, and that revenue growth will support stock upside over the next 12 months.”To this end, Gershell stands with the bulls, reiterating an Outperform rating. At $48, his price target brings the upside potential to 123%. (To watch Gershell’s track record, click here)What does the rest of the Street have to say? 3 Buy ratings and 1 Hold have been issued in the last three months. As a result, URGN receives a Strong Buy consensus rating. In addition, the $44 average price target suggests 104% upside potential. (See URGN stock analysis on TipRanks)Ayala Pharmaceuticals Inc. (AYLA)Last but not least we have Ayala Pharmaceuticals, which is focused on developing targeted therapies for cancers in which Notch activation is a known tumor driver. Based on the progress across its development pipeline, Oppenheimer sees big gains in store.Oppenheimer analyst Jay Olson thinks AYLA’s technology makes it a stand-out. Its two candidates, AL101 and AL102, which are in-licensed from Bristol Myers, are gamma-secretase inhibitors that target aberrant activation of Notch signaling in cancer cells.Notch signaling plays an important role in normal cell development, and perturbations can cause malignant transformation. “We believe Notch targeted therapies hold promise in addressing unmet clinical needs,” Olson commented.The analyst added, “The Notch mutational landscape is diverse, and the underlying science is evolving. AYLA is building a bioinformatics database around Notch to better characterize and identify Notch-activating mutations. Additionally, AYLA is collaborating with partners developing diagnostic tests for Notch-activating mutations, both at DNA and RNA levels. We believe these initiatives benefit AYLA in the long term by identifying responders and expanding the addressable patient population.”Despite the challenges presented by COVID-19, critical catalysts remain on track. The company is set to present new interim data from the Phase 2 ACCURACY open-label study of AL101 in R/M ACC at the mini oral head and neck cancer section of ESMO. Looking at the available data, a recent interim analysis in one cohort showed 69% DCR.As for the second cohort, it is evaluating a 6mg once-weekly dosing of AL101. “We view the efficacy and safety data from the 6mg dosing cohort as important for the registration-enabling studies, and we anticipate similar interim data readout in 1H21,” Olson said.Adding to the good news, AYLA is on track to kick off patient dosing in the Phase 2 TENACITY study of AL101 in R/M TNBC by YE20 after the IND was cleared by the FDA in April. In 2021, AYLA plans to initiate two additional Phase 2 studies including AL102 for desmoid tumors and AL101 for r/r T-ALL.“Springworks Therapeutics recently announced the completion of patient enrollment of the Phase 3 DeFi trial of nirogacestat in desmoid tumors with topline data expected mid-2021, which should provide read-across to AYLA’s AL102 program,” Olson noted.Given all of the above, Olson opined, “We’re encouraged by AYLA’s advantages along several dimensions, including its drug candidates, cancer indication selection, and focus on identifying Notch-activating mutations while developing diagnostics. AYLA’s Notch targeted approach should address unmet clinical needs for patients with rare but aggressive cancers.”It should come as no surprise, then, that Olson stayed with the bulls. To this end, he kept an Outperform rating and $23 price target on the stock, implying 123% upside potential. (To watch Olson’s track record, click here)Looking at the consensus breakdown, 2 Buys and 1 Hold have been published in the last three months. Therefore, AYLA gets a Moderate Buy consensus rating. Based on the $19.83 average price target, shares could climb 92% higher in the next year. (See AYLA stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
Biden reaches out to Latino voters with plan to tackle inequalities
Joe Biden’s election campaign on Tuesday unveiled a plan to address the economic inequalities facing Latinos in America amid financial turmoil caused by the coronavirus pandemic, which has disproportionately harmed communities of color.
The plan was introduced a day after the anniversary of the mass shooting in El Paso, Texas, that took the lives of 23 people and where the shooter is accused in federal court of deliberately targeting Hispanics.
It comes as Biden, the presumptive Democratic nominee to face Donald Trump in November, attempts to build a bridge to Latino voters, who are poised to make up the largest share of US voters who are people of color in this election.
Senior campaign officials announced plans and commitments focused on investing in the economic mobility of Latinos, starting with education and healthcare, as well as a commitment to support the building of a Smithsonian Latino museum on the National Mall in Washington DC.
Biden had previously promised to introduce a sweeping immigration plan on his first day in office, including protecting recipients of the Daca program, affording protections and rights to qualifying, young, undocumented immigrants, known as Dreamers– and also undoing the Trump administration’s hardline international asylum policies.
“The policies of [the Trump] administration amount to an onslaught of violence and fear against the community. That ends when Joe Biden is president,” a senior campaign official said on a call with reporters on Tuesday morning.
Polling shows that while immigration remains a priority for Latino voters, so is healthcare, the economy and education. Young Latinos, like young voters across several demographics, say they care about climate change and racial justice.
Biden previously unveiled the “Lift Every Voice” agenda for African American communities, which included a call for the justice department to prioritize prosecuting hate crimes, and economic plans to help Black Americans affected by the coronavirus pandemic.
His Latino agenda also overlaps with Biden’s “Build Back Better” plan, an economic agenda that includes manufacturing, climate and caregiving. The plan promises “far reaching economic investment” into Latino communities through a first time homeowner credit and investment into Hispanic serving educational institutions. Its healthcare component promises to “tackle social determinants of health” by building on the Affordable Care Act.
The campaign reiterated promises to reshape the legal immigration system that the Trump administration has steadily dismantled. As well as hiring more immigration judges for the overstretched system, the campaign said it will review Trump’s decision to end temporary protected status (TPS), a longstanding program designed to prevent foreign nationals in the US from being deported back to countries devastated by natural disaster or civil unrest.
As president, Biden would create a path to citizenship for certain TPS recipients who have lived in the US for decades, the campaign said.
Since the primary, the campaign has moved left on immigration amid pressure from liberal activists. Still, Biden has resisted calls from progressives to eliminate Ice, the immigration and customs enforcement agency formed in the aftermath of the 9/11 terrorist attacks on the US, or to decriminalize undocumented border crossings, a proposal some of his primary rivals supported.
The plan comes as polling shows Biden leading Trump nationally and in key battleground states, including Florida and Arizona, where Latinos will make up a decisive share of the electorate. Yet some polls show Biden’s support waning among Latino voters, and particularly young Latinos who preferred his leftwing rival, Senator Bernie Sanders, during the primary.
With less than 100 days until the election, Biden’s campaign has ramped up its efforts to reach these voters. In recent weeks, the campaign has made several high-profile hires, including Julie Chavez Rodriguez, the granddaughter of Cesar Chavez, and Matt Barreto, the founder of Latino Decisions, a top Democratic polling firm. It also announced a $1m investment in Spanish-language outreach.
In 2016, Trump won nearly 30% of the Hispanic vote, a margin that has remained largely consistent.
There are signs that may be changing as a result of Trump’s handling of the coronavirus and his escalation of anti-immigrant sentiment and bigoted rhetoric. In the first months of 2020, 34% of Hispanics approved of Trump, according to Gallup. In the period from late May to June, that fell to 26%.
The cornerstone of the Trump campaign’s Latino outreach is in Florida, a state critical to his re-election prospects. But the state’s Hispanic electorate – once dominated by conservative Cuban Americans – is changing with an influx of Puerto Ricans to central Florida. The Biden campaign says it is investing heavily in these voters as it tries to pry the state from Trump in November.
Meanwhile, the Biden campaign is looking to turn out Latinos in rust belt swing states like Pennsylvania and Wisconsin, that Trump won by the narrowest margins in 2016.
• This article was amended on 5 August 2020 to remove a term inconsistent with the Guardian’s style guidelines on references to race.
6 Potential Bankrupt Companies to Watch Thanks to Pandemic Woes
This year has accelerated emerging trends leading to many bankrupt companies. Prior to the novel coronavirus pandemic, sectors like energy and oil were falling out of favor to a degree. Clean energy and technology trends led to that shift. Price wars and the pandemic supercharged the decline in oil. Retail has been absolutely crushed, and the same is true of entertainment stocks. This has accelerated the decline of weaker stocks in those respective sectors.
The result is that multiple equities are now on bankruptcy watch.
Investors have shown a lot of propensity for risk and somewhat surprisingly have flocked to these equities. What follows is a discussion of stocks that are in dire straits. This includes the following:
InvestorPlace – Stock Market News, Stock Advice & Trading Tips
Oasis Petroleum (NASDAQ:OAS)
Remark Holdings (NASDAQ:MARK)
Twinlab Consolidated Holdings (OTCMKTS:TLCC)
CBL & Associates Properties (NYSE:CBL)
Dave & Buster’s (NASDAQ:PLAY)
AMC Entertainment (NYSE:AMC)
None of these names are truly bankrupt companies yet. In fact, some of them may bounce back. But if you’re betting on a comeback in these stocks, remember that they will need to change fundamentally. Let’s take a closer look at what’s going on with each of these companies now.
Future Bankrupt Companies: Oasis Petroleum (OAS)
Oasis Petroleum is in dire straits. After hiring bankruptcy lawyers and missing debt payments the indicators couldn’t be any clearer. OAS stock has been in decline for the past 5 years.
Most recently, it skipped a $30 million interest payment on convertible 2022 notes. Oil and gas producers have been particularly hard hit during the pandemic. This continues a trend in the sector, which has seen price wars, growing green energy interest and demand bottom as people shelter in their homes.
The trend doesn’t show any signs of abating.
According to BloombergLaw:
“Oil and gas bankruptcies have accelerated this year as the coronavirus slows the economy and tamps demand. At least 36 companies have sought Chapter 11 protection in the first three quarters of 2020, according to a report from law firm Haynes and Boone LP. More than 240 producers have filed for bankruptcy since 2015.”
The company has been in distress for several years having had an operating loss for each of the past 3 years. During that same period, the firm issued $430 million in new debt. It also warned that it might be a going concern should it not be able to restructure its current debt.
Remark Holdings (MARK)
Source: Angyalosi Beata / Shutterstock.com
According to its investor relations page, Remark Holdings is developing on AI focused software and business solutions. These are certainly areas that investors are interested in. But MARK stock might be one of the next bankrupt companies of 2020.
Notably, the company has been on shaky footing for the past decade. It has been volatile but traded in the range of $5. It spiked above $14 in early 2018 and has been in sharp decline thereafter.
The company plans to hold a vote Oct. 21 to increase the number of authorized common stock shares to 175,000,000. The company also dismissed its previous auditor on Aug. 31.
Remark has incurred $359.1 million in losses since its inception. The company’s Altman-Z score is -22.9, which indicates extreme distress. Anything under 1.81 indicates bankruptcy is a serious possibility.
Twinlab Consolidated Holdings (TLCC)
If you take nutritional supplements, there’s a decent chance you’ll be familiar with the next company on this bankruptcy list. TwinLabs sells supplements and has been active in the nutrition space since 1968.
In the company’s most recent 10-Q filing it raised questions about its own ability to continue as a going concern. Shares are traded on the pink markets at a current price of 10 cents.
Given that larger, more well-known vitamin retailer GNC filed for bankruptcy and Twinlab has raised its own warnings, signs look dire. GNC will close more than 1,000 of its brick-and-mortar locations.
CBL & Associates Properties (CBL)
Technically CBL & Associates is not on bankruptcy watch as it has already signaled its intent to file for Chapter 11 protection on Oct. 1. Under the agreement $900 million of debt and $600 million of other obligations were eliminated. Maturity on other outstanding debt was pushed out to later dates. As a commercial real estate investment trust operating commercial mortgages it was particularly hurt by the pandemic.
CBL CEO Stephen D. Lebovitz was positive regarding restructuring, stating:
“We also appreciate the confidence in the CBL organization and leadership team shown by the noteholders as we’ve worked collaboratively to find a solution that benefits all company stakeholders. Our goal is for this process to proceed as smoothly and as quickly as possible with no disruption to CBL’s operations. Once the process is complete, we will emerge as a stronger and more stable company, with an enhanced ability to execute on our key strategies of diversifying our sources of revenue and transforming our properties from traditional enclosed malls to suburban town centers. As a result, we will be better positioned to grow our business over the near and long term.”
However, CBL stock has remained in the 20 cent range even after the news. So while the company likely has the financing to continue operations into the future, investors are not impressed that the restructuring will lead to positive results moving forward.
This doesn’t bode well for the company as other companies nearing bankruptcy have seen a lot of investor interest during the pandemic.
Dave & Buster’s (PLAY)
Source: Jeff Bukowski/Shutterstock.com
PLAY stock recently jumped on news that a few analysts rated it a buy. Such news can easily spur a buying run by the markets. But the company has the same problems it had prior to that vote of confidence. In fact, the issues have been magnified due to the pandemic.
“The hospitality industry has been and will be hit the hardest by the pandemic,” wrote Antoinette Tessmer, professor of practice in the Finance Department, Broad College of Business, Michigan State University, in an email to InvestorPlace. “Think of what our families have done over the last six months: we cancelled vacations, we restrain from eating out, we avoid large crowds and unfamiliar surroundings. Think of how conducting business has evolved in the last six months: we work from and eat at home, virtual meetings are the new normal, we do not “travel for business” any longer. Those behaviors have directly impacted restaurants, hotels, casinos, resorts, i.e., the hospitality industry.”
The company is in a period of volatility and has warned that it needs to restructure debt. As per Dave & Buster’s most recent 10-Q filing, it has $224 million in cash and equivalents, and $731 million in long-term debt. In the current operating environment such imbalances can spiral. It reported an operating income loss of $142.5 million through Aug. 2. Total comprehensive income was $68 million through the 26 weeks prior to Aug. 2, 2019 for the firm. In the same period in 2020 debt has increased by $99 million. That means the company has to have a 26 week period to erase roughly $70 million of that $99 million. The company would then be $30 million short of erasing new debt.
Despite the trading volatility that has seen PLAY stock pop, investors should be aware that the company is getting worse, not better. All of that long-term debt is more than a minor problem. It is cause for a company to become insolvent. Dave & Buster’s has stated going concern issues and essentially needs that debt to be forgiven, and or restructured.
But then what? It isn’t exactly the sexiest company is it? Arcades and fast casual dining are lots of fun, but not exactly an area ripe for investment returns.
AMC Theatres (AMC)
Source: Helen89 / Shutterstock.com
AMC opened over 35 theatres last week and has more than 460 open nationwide. This is of course a positive from a revenue and operational perspective. The company is highlighting its cleanliness standards amid the pandemic stating:
“AMC is coming off our most successful weekend since reopening, thanks in large part to Warner Bros. release of TENET. And now, with more than 35 more AMC theatres opening this week, we will be showing movies in nearly 80 percent of our U.S. circuit. That is another encouraging sign that our industry is beginning its way back … [N]ew AMC Safe & Clean safety protocols are clearly resonating with our guests. We’re seeing record-high guest scores for the cleanliness of our theatres, far exceeding the marks we’ve received in the decades we’ve been tracking guest feedback.”
Yet, the company has serious problems that extend beyond the coronavirus. And that issue makes it one of the next potential bankrupt companies to watch.
To be sure, the company’s problems have been exacerbated by the pandemic, but they existed long before. AMC stock will benefit by adhering to new cleanliness standards. But the company must tackle debt. Based on the figures that I see, that may be impossible.
AMC has massive corporate debt and massive operating lease liabilities. Based on cash flows and current cash on hand, the math looks murky at best. In fact, it looks downright bad. Simply consider the firm’s operating activity cash flows as they relate to debt and lease liabilities and as an investor you’ll see why this firm is on bankruptcy watch.
Last year (2019) was a very bad year for AMC. This year has been an absolute catastrophe. In the first six months of 2019, AMC showed an operating loss of $80.8 million. Pretty bad. It then had $265 million in cash and corporate debt of $4.73 billion. Operating lease liabilities were nearly $5 billion at that time. The company now has nearly $500 million in cash. But the $80.8 million loss it posted in the first half of 2019 looks like nothing now. The company posted a net operating loss of $2.73 billion in the first half of 2020. AMC’s accumulated deficit for the first half of 2020 is $3.46 billion. That’s a lot of movie tickets, popcorn and soda that needs to be sold.
Joking aside, it seems insurmountable.
On the date of publication, Alex Sirois did not have (either directly or indirectly) any positions in the securities mentioned in this article.
Alex Sirois is a freelance contributor to InvestorPlace whose personal stock investing style is focused on long-term, buy-and-hold, wealth-building stock picks. Having worked in several industries from e-commerce to translation to education and utilizing his MBA from George Washington University, he brings a diverse set of skills through which he filters his writing.
More From InvestorPlace
The post 6 Potential Bankrupt Companies to Watch Thanks to Pandemic Woes appeared first on InvestorPlace.
Woman to lead Rochester police after Daniel Prude’s death
ROCHESTER, N.Y. (AP) — Rochester Mayor Lovely Warren tapped a Black woman to become the new interim city police chief, saying Saturday she will bring a “fresh approach to policing” amid the tumultuous aftermath to Daniel Prude’s death.
Cynthia Herriott-Sullivan, who retired from the department in 2009 as a lieutenant, will become the first woman to head the police department on Oct. 14.
Warren fired former Police Chief La’Ron Singletary this month after police body camera video was released of Prude, a Black man who died several days after officers put a hood over his head and pressed his face into the pavement on March 23.
The video’s release nearly six month after Prude’s death sparked days of protests in the city, as well as insistent calls for police reform and the mayor’s resignation. Warren lauded Herriott-Sullivan’s police experience and ties to the community and said she will help her “bridge the gap” between the police and residents.
“I am confident that she will bring a different perspective and instill a fresh approach to policing, both of which are very much needed in our city, particularly at this difficult time,” Warren said at a news conference.
Herriott-Sullivan will take over a police department in disarray since Prude’s relatives released the video. Warren claimed Singletary had initially misled her about the circumstances of the death. Other senior police officials have announced their retirements or departures from top command positions.
A week ago, the city by Lake Ontario was further traumatized when gunfire at a backyard party killed two teenagers and wounded 14 others. Police have yet to announce arrests in that case.
Herriott-Sullivan is currently the interim deputy executive director at the Rochester Housing Authority. She told reporters that despite tough times, she believes the community can work together in the city she loves.
“Ironically, I left law enforcement because I wanted to have a bigger hand in helping people stay out of jail rather than putting them in,” she said. ”And so I moved on to roles that helped me in in dealing with criminal justice disparities.”
Warren said earlier this month that the interim chief would serve until June, giving the city time to conduct a national search for a permanent replacement.
- Browns elevate A.J. Green from the practice squad for Week 3
- Biden reaches out to Latino voters with plan to tackle inequalities
- 6 Potential Bankrupt Companies to Watch Thanks to Pandemic Woes
- How Paulo Costa Turned His Loss in The Ultimate Fighter Into His Motivation
- NCAA Football Week 4: An unpredictable 2020 ahead
- Woman to lead Rochester police after Daniel Prude’s death
- 4 Top Stock Trades for Monday: RAD, NCLH, PENN, UNH
- Jets vs. Colts: Preview, predictions, what to watch for
- “Getting Better And Better”: Johanna Konta Prepares for Opening Round Challenge Against Coco Gauff
- Boost Your Retirement Income and Avoid Taxes With This Smart Move
Entertainment1 week ago
Danish TV show ‘Ultra Strips Down’ records kids eyeing naked adults
Sports News3 days ago
US Olympian Chloe Dygert crashes over guardrail in cycling accident
Sports News3 weeks ago
Fantasy Football Auction Draft strategy: Tips, advice for spending your 2020 player budget wisely
Sports News3 weeks ago
NBA 2K21 Cover Star Damian Lillard Reveals His Issues With the Game
Tech6 days ago
iOS 14 basics: how to add widgets to your iPhone’s home screen
Sports News6 days ago
Fantasy Football Buy-Low, Sell-High Stock Watch: Leonard Fournette, Stefon Diggs among movers heading into Week 3
Sports News3 weeks ago
NBA playoff bracket 2020: Updated standings, seeds & results from each round
Sports News2 weeks ago
NFL Analyst Takes a Cheeky Dig on Browns Stars Odell Beckham Jr. and Baker Mayfield